Skip to content
Triangle logo TriangleGet started
← Full study record

NCT00616642 · OUTCOME

Efficacy of Rosiglitazone Maleate on Cushing Disease

Rosiglitazone in Treating Patients With Pituitary Tumors · Source last updated 2020-08-14

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
Not reported
Unit
Not reported
Interval / dispersion
Not reported
Time frame
12 months

What was measured

Reduction in pituitary tumor volume by over 50% as assessed by MRI to measurements made at baseline.

Analysis population: No data was analyzed for this outcome measure as there was insufficient data to perform analysis.

Groups in this outcome

Group 1 (ACTH-secreting Adenomas)

Patients receive 4 mg oral rosiglitazone maleate once daily in week 1 and then 8 mg once daily beginning in week 2 and continuing for up to 6 months in the absence of disease progression or unacceptable toxicity. rosiglitazone maleate : Given orally

Group 2 (Non-secreting Macroadenomas)

Patients receive 4 mg oral rosiglitazone maleate once daily in week 1 and then 8 mg once daily beginning in week 2 and continuing for up to 12 months in the absence of disease progression or unacceptable toxicity. rosiglitazone maleate : Given orally

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
Group 1 (ACTH-secreting Adenomas)0
Group 2 (Non-secreting Macroadenomas)0

Reported measurements

No numerical measurement classes were posted for this outcome. Missing is not zero.

Complete source fields
denoms
  1. counts
    1. group Id
      OG000
      value
      0
    2. group Id
      OG001
      value
      0
    units
    Participants
description
Reduction in pituitary tumor volume by over 50% as assessed by MRI to measurements made at baseline.
groups
  1. description
    Patients receive 4 mg oral rosiglitazone maleate once daily in week 1 and then 8 mg once daily beginning in week 2 and continuing for up to 6 months in the absence of disease progression or unacceptable toxicity. rosiglitazone maleate : Given orally
    id
    OG000
    title
    Group 1 (ACTH-secreting Adenomas)
  2. description
    Patients receive 4 mg oral rosiglitazone maleate once daily in week 1 and then 8 mg once daily beginning in week 2 and continuing for up to 12 months in the absence of disease progression or unacceptable toxicity. rosiglitazone maleate : Given orally
    id
    OG001
    title
    Group 2 (Non-secreting Macroadenomas)
population Description
No data was analyzed for this outcome measure as there was insufficient data to perform analysis.
reporting Status
POSTED
time Frame
12 months
title
Efficacy of Rosiglitazone Maleate on Cushing Disease
type
PRIMARY

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice